Revolution Medicines, Inc. (NASDAQ:RVMD) Accelerates Toward Clinical Milestones, Near‑Term Upside Bias Expected
Revolution Medicines advances a heavy clinical agenda while technical momentum favors continuation; fundamentals show deep R&D spend and a cash-rich balance sheet that underpin near‑term clinical execution but leave valuation stretched.








